Switzerland-based biotechnology firm Mabylon AG announced that it has raised a total of $37 million.

The funding will allow Mabylon to advance its lead program MY006, a tri-specific antibody neutralizing peanut allergens “to completion of a Phase Ia/b trial in 2027 with the goal to generate robust safety and preliminary efficacy data.”

The funding combines a capital increase and a convertible loan. The funds are provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Roche.

“In addition, the funding will enable Mabylon to further develop its discovery and pre-clinical programs,” said Mabylon.

“These include MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nuts allergens.

‘The funding will also support development of MY011, an antibody product for treating grass pollen allergies.”

At a shareholders’ assembly, Dr. Thomas Hecht was elected as a new member of Mabylon’s Board of Directors. He succeeds Prof. Adriano Aguzzi, whose term ended in June 2025.

Gottlieb Keller, Chairman of Mabylon’s Board of Directors, said: “MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need. The funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline.”

Mabylon CEO Alcide Barberis said: “This is a strong validation of our approach using human-derived, multi-specific antibodies for the treatment of allergies.”